PT1135158E - Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica - Google Patents
Vacinas intensificadas a base de peptidos de imunoglobulina e quimericaInfo
- Publication number
- PT1135158E PT1135158E PT99963705T PT99963705T PT1135158E PT 1135158 E PT1135158 E PT 1135158E PT 99963705 T PT99963705 T PT 99963705T PT 99963705 T PT99963705 T PT 99963705T PT 1135158 E PT1135158 E PT 1135158E
- Authority
- PT
- Portugal
- Prior art keywords
- immunogenic polypeptides
- methods
- mammal
- ige
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 108091006116 chimeric peptides Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10665298P | 1998-11-02 | 1998-11-02 | |
US09/401,636 US6913749B2 (en) | 1998-11-02 | 1999-09-22 | Immunogenic polypeptides for inducing anti-self IgE responses |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1135158E true PT1135158E (pt) | 2006-05-31 |
Family
ID=26803871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99963705T PT1135158E (pt) | 1998-11-02 | 1999-10-21 | Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica |
Country Status (18)
Country | Link |
---|---|
US (3) | US6913749B2 (pt) |
EP (1) | EP1135158B1 (pt) |
JP (2) | JP4205861B2 (pt) |
KR (1) | KR100559918B1 (pt) |
AT (1) | ATE314087T1 (pt) |
AU (1) | AU771889B2 (pt) |
CA (1) | CA2348756A1 (pt) |
DE (1) | DE69929240T2 (pt) |
DK (1) | DK1135158T3 (pt) |
ES (1) | ES2255325T3 (pt) |
HK (1) | HK1042844A1 (pt) |
HU (1) | HUP0105392A3 (pt) |
IL (1) | IL142582A0 (pt) |
NO (1) | NO20012135L (pt) |
NZ (1) | NZ511079A (pt) |
PL (1) | PL348611A1 (pt) |
PT (1) | PT1135158E (pt) |
WO (1) | WO2000025722A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
EP1967205B1 (en) * | 2000-08-30 | 2012-10-10 | Pfizer Products Inc. | Anti-IgE vaccines |
US20020172673A1 (en) * | 2000-09-06 | 2002-11-21 | Pharmexa A/S | Method for down-regulating IgE |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
CA2698079C (en) | 2001-02-20 | 2015-01-13 | Ortho-Mcneil Pharmaceutical, Inc. | A cell therapy method for the treatment of tumors |
WO2002092773A2 (en) | 2001-05-15 | 2002-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
JP2003047482A (ja) | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性IgEワクチン |
CA2486464A1 (en) * | 2002-05-21 | 2003-11-27 | Resistentia Pharmaceuticals Ab | Chimeric ige polypeptides and host cells |
JP2006510588A (ja) * | 2002-09-05 | 2006-03-30 | レジステンシア ファーマシューティカルズ アーベー | アレルギーワクチン |
US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
ES2622562T3 (es) | 2008-12-09 | 2017-07-06 | Pfizer Vaccines Llc | Vacuna de péptido CH3 de IgE |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
JP5918851B2 (ja) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | IgEペプチドワクチン |
RU2018130010A (ru) | 2016-02-16 | 2020-03-17 | Регенерон Фармасьютикалз, Инк. | Животные, отличные от человека, имеющие мутантный ген кинурениназы |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767842A (en) | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
US5698201A (en) | 1973-05-07 | 1997-12-16 | The Ohio State University | Method for treatment of antigenically modified polypeptides |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4483793A (en) | 1982-10-04 | 1984-11-20 | The Regents Of The University Of California | Dimeric oligopeptides as heptenic epitopic sites for hepatitis |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
GB8727045D0 (en) | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
JP2724625B2 (ja) | 1987-12-31 | 1998-03-09 | タノックス・バイオシステムズ・インコーポレーテッド | IgE産出性Bリンパ球上の独特な抗原決定基 |
US5254671A (en) * | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8910263D0 (en) | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
US5955076A (en) | 1989-06-15 | 1999-09-21 | Peptide Therapeutics Limited | Immunoactive peptides and antibodies and their use in anti-allergy treatment |
WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
US5733553A (en) | 1989-09-29 | 1998-03-31 | Talwar; Gursaran Prasad | Recombinant birth control vaccine |
WO1991011456A1 (en) | 1990-01-23 | 1991-08-08 | Tanox Biosystems, Inc. | EXTRACELLULAR SEGMENTS OF HUMAN ε IMMUNOGLOBULIN ANCHORING PEPTIDES AND ANTIBODIES SPECIFIC THEREFOR |
DE69112225T2 (de) | 1990-05-25 | 1996-01-04 | Peptide Therapeutics Ltd | Immunodiagnostische probe für gelenkrheumatismus. |
US5196197A (en) | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
EP0561960A1 (en) * | 1990-12-13 | 1993-09-29 | Immunex Corporation | Leukemia inhibitory factor receptors |
SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
US5837686A (en) | 1991-11-25 | 1998-11-17 | Peptide Therapeutics Limited | Peptides and antibodies for treatment of rheumatoid arthritis |
WO1994005698A1 (en) | 1992-09-01 | 1994-03-17 | United Nations Industrial Development Organization | Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum |
AU5361794A (en) | 1992-10-14 | 1994-05-09 | Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
US5762931A (en) | 1992-12-31 | 1998-06-09 | National Institute Of Immunology | Anti-cancer utility of HCG vaccines |
US5532142A (en) * | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
US5501855A (en) | 1993-09-02 | 1996-03-26 | Talwar; Gursaran P. | Neem oil as a male contraceptive |
DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
US5874085A (en) * | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
FR2715304B1 (fr) | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
JPH09510975A (ja) | 1994-03-28 | 1997-11-04 | ユナイテッド・バイオメディカル・インコーポレイテッド | アレルギー治療用合成ペプチドベース免疫原 |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
EP0787150A1 (en) | 1994-10-25 | 1997-08-06 | United Biomedical, Inc. | SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY |
GB9422294D0 (en) | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
ES2230566T3 (es) | 1995-07-17 | 2005-05-01 | Medivir Uk Ltd | Inhibidores de la cisteina proteasa para el tratamiento de enfermedades alergicas mediadas por la inmunoglobulina e (ige). |
ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
RU2193413C2 (ru) | 1996-03-01 | 2002-11-27 | Новартис Аг | Пептидные иммуногены для вакцинации и лечения аллергии |
AU730477B2 (en) | 1996-08-05 | 2001-03-08 | President And Fellows Of Harvard College | MHC binding peptide oligomers and methods of use |
HUP0001930A3 (en) | 1997-04-15 | 2001-10-29 | Pharmexa As | Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
AU2674299A (en) | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
MXPA01003503A (es) | 1998-10-05 | 2005-01-14 | Pharmexa As | Nuevos metodos terapeuticos de vacunacion. |
IL143441A0 (en) | 1998-11-30 | 2002-04-21 | Cytos Biotechnology Ag | Non-naturally occuring antigen arrays and processes for the preparation thereof |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
AU777952B2 (en) | 1999-04-23 | 2004-11-04 | Pharmexa A/S | Method for down-regulating IL5 activity |
AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
US20020172673A1 (en) | 2000-09-06 | 2002-11-21 | Pharmexa A/S | Method for down-regulating IgE |
WO2002102320A2 (en) | 2001-06-15 | 2002-12-27 | Tanox, Inc. | Fce fusion proteins for treatment of allergy and asthma |
-
1999
- 1999-09-22 US US09/401,636 patent/US6913749B2/en not_active Expired - Fee Related
- 1999-10-21 JP JP2000579167A patent/JP4205861B2/ja not_active Expired - Fee Related
- 1999-10-21 PT PT99963705T patent/PT1135158E/pt unknown
- 1999-10-21 NZ NZ511079A patent/NZ511079A/en not_active IP Right Cessation
- 1999-10-21 AT AT99963705T patent/ATE314087T1/de not_active IP Right Cessation
- 1999-10-21 WO PCT/SE1999/001896 patent/WO2000025722A2/en active IP Right Grant
- 1999-10-21 EP EP99963705A patent/EP1135158B1/en not_active Expired - Lifetime
- 1999-10-21 IL IL14258299A patent/IL142582A0/xx not_active IP Right Cessation
- 1999-10-21 DK DK99963705T patent/DK1135158T3/da active
- 1999-10-21 HU HU0105392A patent/HUP0105392A3/hu not_active Application Discontinuation
- 1999-10-21 PL PL99348611A patent/PL348611A1/xx not_active Application Discontinuation
- 1999-10-21 ES ES99963705T patent/ES2255325T3/es not_active Expired - Lifetime
- 1999-10-21 CA CA002348756A patent/CA2348756A1/en not_active Abandoned
- 1999-10-21 AU AU20081/00A patent/AU771889B2/en not_active Ceased
- 1999-10-21 DE DE69929240T patent/DE69929240T2/de not_active Expired - Lifetime
- 1999-10-21 KR KR1020017005276A patent/KR100559918B1/ko not_active IP Right Cessation
-
2001
- 2001-04-30 NO NO20012135A patent/NO20012135L/no unknown
-
2002
- 2002-03-26 HK HK02102312A patent/HK1042844A1/xx not_active IP Right Cessation
- 2002-06-19 US US10/176,664 patent/US7459158B2/en not_active Expired - Fee Related
-
2003
- 2003-09-29 US US10/673,594 patent/US20040076625A1/en not_active Abandoned
-
2005
- 2005-09-07 JP JP2005258648A patent/JP4188353B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ511079A (en) | 2003-08-29 |
DE69929240T2 (de) | 2006-08-31 |
US20030031663A1 (en) | 2003-02-13 |
HUP0105392A3 (en) | 2008-04-28 |
JP4188353B2 (ja) | 2008-11-26 |
NO20012135L (no) | 2001-06-25 |
WO2000025722A3 (en) | 2000-10-12 |
US20040076625A1 (en) | 2004-04-22 |
DK1135158T3 (da) | 2006-05-15 |
AU2008100A (en) | 2000-05-22 |
WO2000025722A2 (en) | 2000-05-11 |
US20010038843A1 (en) | 2001-11-08 |
DE69929240D1 (de) | 2006-02-02 |
HK1042844A1 (en) | 2002-08-30 |
US7459158B2 (en) | 2008-12-02 |
KR20010089364A (ko) | 2001-10-06 |
KR100559918B1 (ko) | 2006-03-13 |
EP1135158B1 (en) | 2005-12-28 |
CA2348756A1 (en) | 2000-05-11 |
ATE314087T1 (de) | 2006-01-15 |
JP2006068015A (ja) | 2006-03-16 |
AU771889B2 (en) | 2004-04-08 |
US6913749B2 (en) | 2005-07-05 |
IL142582A0 (en) | 2002-03-10 |
HUP0105392A2 (hu) | 2002-04-29 |
ES2255325T3 (es) | 2006-06-16 |
JP4205861B2 (ja) | 2009-01-07 |
NO20012135D0 (no) | 2001-04-30 |
JP2002531064A (ja) | 2002-09-24 |
EP1135158A2 (en) | 2001-09-26 |
PL348611A1 (en) | 2002-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1135158E (pt) | Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica | |
NO346167B1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
CY1122505T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
DK1798288T3 (da) | Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder | |
CR9236A (es) | Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas | |
BR0113112A (pt) | Anticorpos, de integrina antidual, composições, métodos e usos | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
DE602004031017D1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
DE69609188D1 (de) | Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus | |
DK1167389T3 (da) | Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf | |
TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
NO20052714D0 (no) | Fremgangsmater og materialer for behandling av inflammatoriske tilstander | |
EP1621209A3 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides | |
WO2002038611A3 (en) | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins | |
WO2004000238A3 (en) | Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines | |
Lou et al. | Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine | |
MY155265A (en) | Anti-dual integrin antibodies, compositions, methods and uses |